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Background: Recent studies suggest that the reported protective effects of statins (HMG-CoA reductase inhibitors)
against community-acquired pneumonia (CAP) and sepsis in humans may be due to confounders and a healthy
user-effect. To directly test whether statins are protective against Streptococcus pneumoniae, the leading cause of
CAP, we examined the impact of prolonged oral simvastatin therapy at physiologically relevant doses in a mouse
model of pneumococcal pneumonia. BALB/c mice were placed on rodent chow containing 0 mg/kg (control),
12 mg/kg (low simvastatin diet [LSD]; corresponds to 1.0 mg/kg/day), or 120 mg/kg (high simvastatin diet [HSD];
corresponds to 10 mg/kg/day) simvastatin for four weeks, infected intratracheally with S. pneumoniae serotype
4 strain TIGR4, and sacrificed at 24, 36, or 42 h post-infection for assessment of lung histology, cytokine production,
vascular leakage and edema, bacterial burden and bloodstream dissemination. Some mice received ampicillin at
12-h intervals beginning at 48 h post-infection and were monitored for survival. Immunoblots of homogenized
lung samples was used to assess ICAM-1 production.
Results: Mice receiving HSD had reduced lung consolidation characterized by less macrophage and neutrophil
infiltration and a significant reduction in the chemokines MCP-1 (P= 0.03) and KC (P= 0.02) and ICAM-1 in the lungs
compared to control mice. HSD mice also had significantly lower bacterial titers in the blood at 36 (P= 0.007) and
42 (P= 0.03) hours post-infection versus controls. LSD had a more modest effect against S. pneumoniae but also
resulted in reduced bacterial titers in the lungs and blood of mice after 42 h and a reduced number of infiltrated
neutrophils. Neither LSD nor HSD mice had reduced mortality in a pneumonia model where mice received
ampicillin 48 h after challenge.
Conclusions: Prolonged oral simvastatin therapy had a strong dose-dependent effect on protection against
S. pneumoniae as evidenced by reduced neutrophil infiltration, maintenance of vascular integrity, and lowered
chemokine production in the lungs of mice on HSD. Statin therapy also protected through reduced bacterial
burden in the lungs. Despite these protective correlates, mortality in the simvastatin-receiving cohorts was
equivalent to controls. Thus, oral simvastatin at physiologically relevant doses only modestly protects against
pneumococcal pneumonia.Background
Statins, or 3-hydroxy-3methylglutaryl coenzymeA (HMG-
CoA) reductase inhibitors, are prescribed to treat elevated
levels of cholesterol and cardiovascular disease. As such
they are among the most commonly prescribed drugs in
the United States and worldwide. While statins can reduce
plasma cholesterol by as much as 30-55%, statins also
have potent anti-inflammatory and immunomodulatory* Correspondence: orihuela@uthscsa.edu
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reproduction in any medium, provided the orproperties that may be beneficial against certain infec-
tious diseases in particular community-acquired pneu-
monia (CAP) [1].
In 2004, a prospective observational cohort study of
individuals admitted to hospital for bacterial infection
found that those taking statins had reduced incidence of
sepsis and intensive care unit (ICU) admission [2].
Retrospective studies by Mortensen et al., determined
that prior statin use was associated with reduced 30-day
mortality in patients admitted with CAP or sepsis [3,4].
Importantly, statin use was shown to reduce the risk of
CAP in patients with diabetes, an established risk factord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ies have reported on the effects of statins on CAP and
sepsis with a recent meta-analysis by Janda et al. report-
ing a strong beneficial effect against pneumonia- and
sepsis-related mortality [6].
Importantly, not all studies identified a protective ef-
fect for statins against CAP [7-9]. For example a recent
2011 study by Yende et al., which accounted for healthy
user effect and indication bias using propensity analysis,
found no evidence for a protective effect in 1895 sub-
jects hospitalized for CAP across 28 U.S. hospitals [9].
Likewise, in a study of 3415 individuals admitted to a
hospital with pneumonia, Majundar et al. found that
prior statin use had no effect on mortality or need for
admission to an ICU [8]. Finally, de Saint Martin et al.
found that statins users had higher ICU admission rates
than non-users, albeit no differences in length of hos-
pital stay or mortality were observed [7]. The authors of
these studies suggest that the protective effects reported
for statins may be due to confounders, a healthy user ef-
fect, and/or indication bias. As results from randomized
control trials are not yet published, direct evidence of
whether statins confer protection against CAP remains
controversial.
Studies investigating the effects of statins on bacterial
infections using laboratory animals have yielded conflict-
ing results and added to the uncertainty. In a mouse
model of Klebsiella pneumoniae pneumonia, lovastatin
administration resulted in increased bacterial outgrowth
that the authors attributed to reduced neutrophil accu-
mulation within the lungs and defects in neutrophil-
dependent intracellular killing [10]. For Staphylococcus
aureus, high-dose statin therapy was shown to enhance
the production of antimicrobial extracellular DNA traps
by phagocytes within the lungs of mice and to protect
against disseminated infection [11,12]. We have recently
shown that short-term simvastatin therapy reduced the
severity of pneumococcal disease in mice with sickle-cell
disease but had no protective effect on young wild type
mice [13]. Statin-mediated protection in the sickle-cell
animals was due to: 1) reduced levels of Platelet-activating
factor receptor, a host-protein that Streptococcus pneu-
moniae co-opts to adhere and invade host cells, and 2)
reduced cytotoxicity of pneumolysin, a cholesterol de-
pendent pore-forming toxin produced by S. pneumoniae.
Of note, for all the animal studies described above, sta-
tins were either administered through a non-oral route,
on a short-term basis, or at doses that far exceed what
would normally be administered to humans for cardio-
vascular disease. Thus the mechanisms that might pro-
tect humans against pneumonia following oral statin
therapy remain in question.
Given the large number of individuals at risk for pneu-
monia, it is important to determine whether prolongedoral statin therapy confers protection against pneumo-
nia and if so the mechanisms that are responsible. For
this reason we examined the effect of 4-week enteric-
delivered simvastatin on the progression and severity
of pneumococcal pneumonia in mice. Our findings in-
dicate that simvastatin therapy reduced bacterial burden,
decreased neutrophil influx, and diminished lung dam-
age, but did not affect overall mortality. These studies
provide experimental evidence supporting the notion
that prophylactic statin therapy can exert protective ben-
efits against CAP in humans; however these effects are
modest in mice at the maximum recommended dose of
simvastatin for humans.
Materials and methods
Mice and simvastatin diet
All experiments were performed in compliance with ap-
proved Institutional Animal Care and Use Committee
protocols. Female 12-16 week old BALB/c mice were
purchased from The Jackson Laboratory (Bar Harbor,
MA). Rodent chow containing simvastatin (Sigma, St.
Louis MO) at 0 mg/kg (control), 12 mg/kg (low simvas-
tatin diet [LSD]), or 120 mg/kg (high simvastatin diet
[HSD]) was prepared by Purina TestDiet (Richmond, IN)
and fed ad libitum for ≥4 weeks. For a 25-30 g mouse
consuming 2-2.5 g of chow per day these diets corre-
spond to 1.0 and 10 mg/kg/day of simvastatin, respect-
ively. Previous studies have confirmed a therapeutic effect
for LSD and HSD by testing for a reduction in serum
cholesterol [14].
Assessment of disease severity
S. pneumoniae serotype 4, strain TIGR4 was grown in
Todd Hewitt Broth at 37°C in 5% CO2 [15]. Animals
were anesthetized with vaporized isoflurane and 105 cfu
in 100 μl phosphate-buffered saline (PBS) was delivered
intratracheally by forced inhalation [16]. Mice were eu-
thanized and bacterial burden in the lungs was assessed
per gram of homogenized tissue. Alternatively, bactere-
mia and mortality was assessed over 7 days [17]. In in-
tervention experiments, beginning at 48 h post-challenge,
mice were administered ampicillin (80 mg/kg) at 12 h
intervals. Lungs sections (5 μm) were stained with He-
matoxylin and Eosin (H&E) and scored in a blind man-
ner based on lung consolidation, evidence of hemorrhage,
and extent of cellular infiltration.
Bronchoalveolar lavage (BAL)
Mice were euthanized by CO2 asphyxiation. Following
surgical visualization of the trachea, BAL was performed
by insertion of a 0.18 gauge angiocatheter and flushing
of the lungs with 0.5 ml ice-cold PBS until a total volume
of 3 ml was obtained. BAL fluid was strained (40-μM)
and centrifuged. The cellular fraction was suspended in
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Figure 1 Simvastatin prophylaxis decreases bacterial burdens
in the lungs. Bacterial titers in the lungs 24 and 42 h after infection
of mice fed the Control, Low or High statin diet and challenged
intratracheally with 1 X 105 cfu. Each circle represents an individual
mouse. Horizontal lines indicate the median; dashed lines indicate
limit of detection Mice receiving statins had significantly lower
bacterial titers in the lungs 42 h after infection. Data are presented
as the mean± SEM. Statistics were determined by a two-tailed
student’s t-test. P< 0.05 was considered significant on comparison to
Control fed mice.
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hemocytometer. Differential cell counts were done fol-
lowing cytospin and staining with a Diff-Quick Staining
Kit (IMEB Inc.); >300 cells were counted in three separ-
ate fields for each mouse.
Albumin and cytokine analysis
Vascular leakage in BAL fluid was assessed using a
mouse albumin ELISA Quantitation Set (Bethyl Labora-
tories, Inc., Montgomery, TX). Levels of Tumor Necrosis
Factor (TNF)α, Interleukin (IL)-6, IL-10, IL-12, Mono-
cyte chemoattractant protein (MCP)-1, and Interferon
(IFN)γ in BAL fluid and serum samples were performed
using a Mouse Inflammatory Cytometric Bead Array (BD
Biosciences). Concentrations of KC were determined
using a DuoSET Mouse CXCL1/KC ELISA kit from R&D
Systems (Minneapolis, MN).
Determination of ICAM-1 protein levels in the lungs
Lungs were homogenized in RIPA buffer containing a
protease inhibitor cocktail (Sigma). Separation of protein
by SDS-PAGE, transfer to nitrocellulose membrane, and
detection was performed using standard immunoblot
methods. Goat polyclonal antibody to ICAM-1 (Santa
Cruz Biotechnology) was used for detection. Relative
protein levels were determined by densitometric analysis
of Western blot bands using a Molecular Imager Gel
Doc XR System (BioRad, Hercules, CA). To ensure that
equal amount of protein had been probed, and to permit
normalization of ICAM-1 across samples, membranes
were stripped and the amount of actin determined using
rabbit anti-actin antibodies (Bethyl Laboratories, Inc.,
Montgomery, TX).
Statistical analysis
For comparisons between cohorts either a One-way
ANOVA or two-tailed Student’s t test was used as indi-
cated. P values <0.05 were considered significant. For
survival analyses a Kaplan-Meier Log Rank Survival Test
was used.
Results
Oral statin prophylaxis decreases the severity of
pneumococcal pneumonia in mice
To determine the effect of simvastatin prophylaxis on
disease severity we first assessed bacterial burden during
pneumonia. Pneumococcal titers in the lungs collected
at 24 h post-infection (hpi) did not significantly differ
between the simvastatin fed and control cohorts
(Figure 1); although bacterial titers in the lungs of mice
on HSD had a trend towards reduced bacterial load
(P= 0.08). At 42 hpi, mice on the control diet had
approximately 50- (P= 0.02) and 100-fold (P= 0.002)
more bacteria in their lungs than mice on LSD and HSD,respectively. In agreement with this reduced bacterial
load, histological analysis of lung sections demonstrated
decreased lung damage with less evidence of lung con-
solidation, edema, and hemorrhage in the HSD mice
versus controls (Figure 2A). Mice receiving LSD had no
discernible difference in lung damage versus controls.
Analysis of BAL fluid for evidence of vascular leakage
demonstrated that mice on HSD had reduced albumin in
their lungs 24 hpi (Figure 2B). No differences in albumin
levels were found between mice receiving the LSD versus
the control diet or in baseline levels of albumin prior to
infection. Thus, HSD seemed to protect vascular integ-
rity during infection.
We subsequently examined the impact of oral simvas-
tatin therapy on development of bacteremia. Following
intratracheal challenge at 24 hpi, bacterial titers in the
blood were not significantly different among all three
groups tested; although mice receiving HSD had lower
median titers compared to mice on the control diet
(P= 0.12) (Figure 3). Between 24 and 36 h, pneumococ-
cal titers in the blood increased at a similar rate for all
mice, nonetheless mice on HSD had significantly fewer
pneumococci in their blood compared to control mice
(P= 0.007). After 36 h, mice receiving the control diet
continued to experience bacterial replication whereas
those on a simvastatin diet maintained or began to clear
bacteria from the blood. At 42 hpi, mice on the HSD
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Figure 2 Simvastatin prophylaxis decreases histopathology and vascular leakage. A) Representative micrographs of Hematoxylin- and
Eosin-stained lung sections from mice 42 h after infection. Note that the high statin fed mice exhibit reduced cellularity and vascular
hemorrhage. Original magnification, 10X. B) Vascular integrity was determined by assessing the amount of albumin present in the BAL fluid by
ELISA prior to and following infection (n = 3/group for uninfected and n= 6/group for infected mice). Data are presented as the mean± SEM.
Statistics were determined by a two-tailed student’s t-test. P< 0.05 was considered significant in comparison to Control fed mice.
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blood compared to control fed mice (P= 0.03).High-dose simvastatin reduces chemokine production in
the lungs
Statins have been reported to reduce cytokine produc-
tion following LPS stimulation of monocytes and de-
crease lung inflammation following instillation of LPS in
healthy human volunteers [18,19]. Thus we investigated
the effect of simvastatin therapy on the local and sys-
temic production of cytokines and chemokines during
pneumococcal pneumonia. At 24 hpi, before bacterial
titers in the lungs were significantly different, no differ-
ences were observed for TNFα, IL-6, IL-10, IL-12, MCP-
1, KC and IFNγ in the BAL fluid or serum of mice on
LSD versus controls (Figure 4A, B). In contrast, mice on
HSD had significant reductions in MCP-1 (P= 0.03) and
KC (P= 0.02) in the BAL fluid but not serum. No differ-
ences were observed for all other cytokines or chemo-
kines in the BALF or in the serum of HSD mice.
Uninfected mice on control, LSD and HSD had un-
altered low levels of cytokines and chemokines presentin the BAL fluid and serum prior to infection (data not
shown).
Statins impact neutrophil influx and ICAM-1 expression
Statins have been reported to reduce neutrophil influx
into the lungs following instillation of LPS and during
K. pneumoniae infection [10]. We therefore assessed
whether oral simvastatin also attenuated cellular influx
into the lungs during pneumococcal pneumonia. Total
cell counts using BAL fluid collected at 24 hpi demon-
strated that mice receiving HSD had significantly less
cellular infiltration compared to control mice (P < 0.001)
(Figure 5A). Notably, infected HSD mice had only a no-
minal increase in cellular infiltrates (P= 0.07 versus con-
trols) versus the mock-infected controls, confirming that
high-dose statins indeed reduced leukocyte influx. In
contrast, mice on control and LSD had a robust and sig-
nificant cellular response versus uninfected controls
(Control, P < 0.001; LSD, P= 0.02).
Although during infection the absolute numbers of
leukocytes in the BAL did not differ between mice on
LSD and control diet, those receiving LSD had signifi-
cantly less neutrophils in the BAL compared to control
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Figure 4 Statins preferentially decrease chemokine production
in the lungs without reducing proinflammatory mediators
during early pneumococcal pneumonia. Control, Low, and High
statin mice were challenged intratracheally with 1 X 105 cfu and
sacrificed 24 h after infection. Collected A) bronchoalveolar lavage
fluid and B) serum were assayed for pro-inflammatory cytokine and
chemokine production by a mouse inflammatory cytometric bead
array or ELISA (n = 12/group). No statistically significant differences in
cytokine production were observed, while the chemokines MCP-1
and KC were significantly decreased in mice receiving the high
statin diet compared to control. Data are presented as the
mean± SEM. Statistics were determined by a two-tailed student’s
t-test. P< 0.05 was considered significant in comparison to Control
fed mice.
Hours after infection 
3 
4 
5 
6 
7 
24 36 48 
B
ac
te
ri
al
 t
it
er
s 
in
 t
he
 b
lo
od
 
L
og
 1
0(
C
F
U
/m
L
) 
Control 
Low 
High  
P=0.007
P=0.03
Figure 3 Mice on simvastatin prophylaxis show enhanced
protection from bacteremia. Bacterial titers in the blood of
challenged mice 24, 36 and 42 h after infection. Mice on Control
(n = 11), Low (n = 11) or High (n = 12) diet were challenged
intratracheally with 1 X 105 cfu. Mice receiving statins had
significantly fewer bacteria in the blood. Data are presented as the
mean± SEM. Statistics were determined by a two-tailed student’s
t-test. P< 0.05 was considered significant.
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had a significant reduction in the number of infiltrating
neutrophils (P < 0.001). Differences in neutrophil num-
bers were dose-dependent with those on the LSD and
HSD at approximately 75% and 25% of the levels ob-
served for the control diet, respectively. Importantly, a
less dramatic effect was observed for macrophages/
monocytes. Only infected mice on HSD had a significant
reduction in numbers versus their infected controls
(P= 0.01) (Figure 5B).
Statins have been found to decrease the up regulation
of adhesion molecules on endothelial cells in several
models of inflammation [20-22]. Because we observed a
dose-dependent reduction in neutrophil influx, yet only
mice on the HSD had lower production of the neutro-
phil chemoattractant KC, we went on to assess whether
statins were reducing neutrophil infiltration by modulat-
ing the upregulation of adhesion molecules. In agree-
ment with the observed reduction in neutrophils influx,
mice receiving statins had a strong dose-dependent re-
duction in the protein levels of ICAM-1 present in the
lungs prior to infection with S. pneumoniae (Control
versus LSD, P= 0.04; Control versus HSD, P= 0.004)
(Figure 6A). Whereas at 24 hpi, only mice on the HSD
continued to have decreased protein levels of ICAM-1
in the lungs (P= 0.02) (Figure 6B). Taken together these
findings suggest that statins exert a dose-dependent ef-
fect to reduce neutrophil infiltration during pneumo-
coccal pneumonia by reducing neutrophil chemotaxisand transcytosis without suppressing pro-inflammatory
mediators required to enhance antibacterial defense
mechanism.
Surivival of infected mice on statins Finally, we sought
to directly test if prophylactic statin therapy improved
disease outcomes in a clinically relevant infection model.
Since individuals with CAP receive antimicrobials, we
tested for survival of mice in a model where beginning
at 48 hpi mice received ampicillin at 12 h intervals. Des-
pite the protective effects observed above, mice on LSD
or HSD had equivalent survival over time as controls
(Figure 7). Thus, the overall protective effects of statins
were modest and may not necessarily impact disease
outcomes in humans.
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Figure 5 Statins decrease leukocyte infiltration into the lungs. A) Total cell counts obtained by bronchoalveolar lavage (BAL) 24 h after
intratracheal infection with 1 X 105 cfu were determined by visual counting using a hemocytometer (n = 6/group). Differential cell counts of
cytospins prepared from the same BAL demonstrating B) lower monocytes/macrophages in mice receiving the high statin diet and C) a dose-
dependent reduction in neutrophil influx 24 h after infection. Data are presented as the mean± SEM. Statistics were determined by a two-tailed
student’s t-test. P< 0.05 was considered significant in comparison to Control fed mice.
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Numerous studies, including recent meta-analyses, have
reported an association between prior statin use and
improved outcomes following CAP and sepsis [6,23].
Conversely, a recent study by Yende et al., in which the
authors accounted for healthy user effect and indication
bias using propensity analysis, found no evidence for a
protective effect of statins on clinical outcomes [9].
Experiments with laboratory animals can directly test
whether statins are protective against infectious diseases.
Unfortunately, studies thus far have been flawed by ei-
ther short-duration of statin therapy, the administration
of too high levels of statins, and non-enteric delivery of
the drug. Thus, at the onset of our study, it was unclear
whether prolonged simvastatin therapy, delivered enteri-
cally for 4 weeks, and at a dose taken by humans for
high cholesterol (LSD; 1.0 mg/kg/day) would be protect-
ive against S. pneumoniae. Most evident from our stud-
ies was the strong dose-dependent effect of simvastatin
on examined parameters; for LSD we observed only
reduced bacterial titers in the lungs at 42 hpi and inter-
mediate reductions in neutrophil influx and ICAM-1 ex-
pression. In contrast, mice receiving HSD (i.e. 10 mg/kg/
day; 10X maximum recommended human dose) had sig-
nificantly reduced bacterial titers in the lungs and blood,less lung damage, and diminished cytokine production
and neutrophil recruitment. Therefore, the dose of statin
received by participating individuals in human trials for
statins should be a key consideration.
Excessive cellular infiltrates is a common complication
of CAP. Likewise, ours is not the first study to suggest
that statins attenuate neutrophil influx or edema during
infection or injury [12,19,24-26]; with a similar effect for
lovastatin (10 mg/kg administered intraperitoneal 20, 12,
and 0.5 h preceding exposure) reported by Fessler et al.
during K. pneumoniae infection [10]. Based on our find-
ings, reduced neutrophil infiltration can now be attribu-
ted to reduced chemokine production (e.g. MCP-1 and
KC) as well as a reduction in ICAM-1 levels that to-
gether reduces the entry of circulating neutrophils and
macrophages into the lungs. Notably, and despite con-
siderable lung protection observed in HSD mice, we
found no significant differences in IL-6 or TNFα levels,
the two pro-inflammatory cytokines most often corre-
lated with severity of CAP [27]. Thus, in our study sim-
vastatin did not prevent a “cytokine storm” and instead
acted through decreased cellular infiltration and vascular
leakage. This cautions against using IL-6 and TNFα as
correlates of protection in human trials. Of note, this
contrasts findings by Ando et al., where pretreatment of
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Boyd et al. BMC Microbiology 2012, 12:73 Page 7 of 9
http://www.biomedcentral.com/1471-2180/12/73the mice with cerivastatin (20 mg/kg i.p. 12 and 1 h be-
fore challenge) reduced serum levels of TNFα and IL-1β
following LPS administration (15 mg/kg i.p.). This differ-
ence may be due to the use of different statins, distinct
routes of drug administration and bacterial challenge,20 
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Figure 7 Survival of simvastatin fed mice following infection
with S. pneumoniae. Kaplan–Meier plot demonstrating percent
survival of challenged mice. Mice on Control (n = 19), Low (n = 19) or
High (n = 20) diet were challenged intratracheally with 1 X 105 cfu.
After 48 h ampicillin (80 mg/kg) was administered every twelve
hours. Significance was determined by Log-Rank test.our use of a lower dose, and because we examined the
response to a Gram-positive bacteria [26]. The latter ap-
plies to all the aforementioned animal studies as well. It
is worth noting that statins have a well-documented
anti-inflammatory effect that is independent of infection.
For example, Müller et al., found that simvastatin treat-
ment limited pulmonary endothelial injury, attenuated
pulmonary hyperpermeability, prevented the recruitment
of leukocytes to the lung, reduced pulmonary cytokine
levels and improved oxygenation in mechanically venti-
lated mice [28]. Thus our findings for HSD are consist-
ent with those of Müller et al.
During pneumonia, neutrophils are the primary ef-
fector cell responsible for clearance of extracellular
bacteria. It was therefore paradoxical that reduced neu-
trophil infiltration was observed in HSD mice simul-
taneously to decreased bacterial burden in their lungs.
In our hands, simvastatin does not have antibacterial
effects in vitro on S. pneumoniae at in vivo concentra-
tions [13,29]. Yet, Jerwood et al. have shown that sim-
vastatin has considerable antimicrobial properties against
Staphylococcus aureus [30]. Thus we cannot directly rule
out killing by simvastatin in vivo. Possible reasons for
the reduction in bacterial burden also include lowered
PAFr expression in the lungs that would decrease bacter-
ial adhesion and/or enhanced killing ability by resident
alveolar macrophages due to enhanced resistance to the
cholesterol-dependent toxin pneumolysin [13]. Although
not tested in our study, high dose statins has also been
reported to increase killing of S. aureus and S. pneumo-
niae by enhancing the formation of phagocyte extra-
cellular traps in mice fed pulverized rodent chow
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S. pneumoniae, killing by extracellular traps remains
controversial as other investigators have shown that
S. pneumoniae is able to resist neutrophil extracellular
traps (NETs) due to the presence of a surface localized
endonuclease that degrades the DNA scaffold of NETs
[31,32].
Importantly, the discrepancy in disease severity in
mice for S. pneumoniae with simvastatin and for K.
pneumoniae with lovastatin, as reported by Fessler et al.
[10], raises the possibility that statins facilitate differen-
tial outcomes depending on the infectious agent. Neu-
trophils are a primary mediator of lung injury during
pneumonia and a study with neutropenic mice infected
with S. pneumoniae demonstrated less lung injury and
improved survival [33,34]. Our findings are consistent
with these previous publications. In addition to the dif-
ferences in the class and delivery of statins used between
our study and that of Fessler et al., another important
consideration is that Gram-negative bacteria do not
produce cholesterol-dependent cytolysins, such as pneu-
molysin. Statins might preferentially protect against
Gram-positive bacteria. Such species-specific effects
would have considerable implications regarding the util-
ity of statins as a prophylactic drug within a hospital
setting where the etiological cause of pneumonia is more
frequently Gram-negative bacteria [35]. This further
suggests that statin studies consider the etiological agent
responsible for CAP.
In our clinical intervention model we observed no pro-
tection for challenged LSD or HSD mice as measured by
survival. Worth consideration is the possibility that
improved survival might have been observed if the ampi-
cillin therapy was begun earlier. This notion is supported
by the reduced bacterial titers in the blood of mice on
LSD and HSD at 42 h hpi. Nonetheless, this observation
suggests that the protective effects of statins are overall
modest; even when a high dose of simvastatin is admi-
nistered. One important caveat is that rodents metab-
olize drugs at different rates than humans and so the
protective effect of statins may be more pronounced in
humans at lower doses. Nonetheless our findings strong-
ly suggest that individuals taking lower levels of statins
would have reduced-protection against CAP versus those
on higher doses. Finally, these observations highlight
the complexity of the clinical question and indicate that
human trials on statins for CAP should have multiple
correlates of protection.
Conclusion
In summary, this study demonstrates that oral statin
therapy may protect against pneumococcal pneumonia
by increasing bacterial clearance, reducing excessive neu-
trophil infiltration, and decreasing vascular permeability.Importantly, a strong dose-dependent effect was observed
for simvastatin with minimal effects on mice adminis-
tered the maximum recommended human dose (i.e. LSD)
and no differences in overall survival observed for mice
on HSD. Our observations help to explain why some
human studies fail to find a protective effect as multiple
correlates of protection are required for testing and mul-
tiple variables most likely affect outcomes including sta-
tin dose, etiological cause of CAP, and severity of CAP at
time of admission.
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